Rituximab as a treatment alternative in sarcoidosis

Belkhou, A.; Younsi, R.; Bouchti, I. El; Hassani, S. El

doi:10.1016/j.jbspin.2008.01.025

Cited by 56 publications

(33 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The effects of rituximab in sarcoidosis patients have not been demonstrated by clinical trial. Three single case reports describe successful effects of this biological agent in refractory multisystem sarcoidosis [84][85][86]. Interestingly, these authors also found this anti-CD20 effective in patients with no response to infliximab and other biological therapies [86].…”

Section: Other Cytokine Modulatorsmentioning

confidence: 98%

Cytokine modulators in the treatment of sarcoidosis

2011

View full text Add to dashboard Cite

Sarcoidosis is a granulomatous lung disease in which several cytokines play a pivotal pathogenetic role. Steroid-resistant disease can be treated with immunosuppressive drugs, antimalarial therapies and recently with anti-TNFα agents. The use of biological agents for the treatment of sarcoidosis springs from research into the pathogenesis of the disease and also from the experience of rheumatologists with other chronic inflammatory diseases. Rituximab, golimumab and ustekinumab are cytokine modulators, useful in the treatment of immunoinflammatory disorders, for which randomized trials to evaluate safety and efficacy in sarcoidosis are not yet available. Novel anticytokine drugs administered alone or in association may offer a new approach to treatment of the disease. This review focuses on recent advances in anti-TNFα agents and cytokine modulators for the treatment of sarcoidosis and their therapeutic prospects.

show abstract

Section: Other Cytokine Modulatorsmentioning

confidence: 98%

Cytokine modulators in the treatment of sarcoidosis

2011

View full text Add to dashboard Cite

show abstract

“…It has been reported as effective for refractory sarcoidosis in case reports [157][158][159][160]. The drug has significant toxicity, including reactions to infusion and increased risk for infections [159,161].…”

Section: Other Agentsmentioning

confidence: 99%

Established and experimental medical therapy of pulmonary sarcoidosis

et al. 2013

View full text Add to dashboard Cite

The treatment options for pulmonary sarcoidosis have increased over the past 10 years. As new treatments have been introduced, the best way to assess and compare treatments remains unknown. The goal of this review is to discuss the standard treatments for pulmonary sarcoidosis, including glucocorticoids, and cytotoxic agents, such as methotrexate, azathioprine and leflunomide, and compare them to the newer biological agents, such as infliximab and adalimumab. We also discuss some novel treatments which are currently being evaluated. To compare these different regimens, we look at the measures used to assess response. These include pulmonary function, chest imaging, steroid sparing potential and, more recently, improvements in quality of life measures. While there is, as yet, no standard assessment for response, there is a growing consensus that response to treatment may include improvement of one or more of the following: forced vital capacity, chest imaging and steroid sparing. Several drugs used for pulmonary sarcoidosis have demonstrated improvement in one or more of these measures.

show abstract

“…97 Rituximab has been used to treat some cases of optic neuropathy, 98 and has also been reported as effective in treating some sarcoidosis patients. 99 Because of differences in toxicities, these drugs may be useful in selected cases. Cyclosporine has also been reported as useful in selected cases.…”

Section: Management Of Neuro-ophthalmic Sarcoidosismentioning

confidence: 99%

Neuro-ophthalmic sarcoidosis

Baughman¹,

Weiss²,

Golnik³

2012

View full text Add to dashboard Cite

Neuro-ophthalmic disease occurs in about a third of patients with neurosarcoidosis. Optic nerve involvement is the most common manifestation, but other cranial nerves and the optic chiasm can be involved. However, there are several other common diseases that cause optic neuropathy, including multiple sclerosis. The diagnosis of sarcoidosis can often be made based on the multi-organ nature of the disease and ancillary testing. Most patients with neuro-ophthalmic sarcoidosis require systemic therapy. While corticosteroids are usually the first step in therapy, cytotoxic agents such as methotrexate and azathioprine have been useful as steroid-sparing agents for chronic disease. The monoclonal antibodies directed against tumor necrosis factor have been reported as effective in refractory cases of neuro-ophthalmic disease.

show abstract

Rituximab as a treatment alternative in sarcoidosis

Cited by 56 publications

References 3 publications

Cytokine modulators in the treatment of sarcoidosis

Cytokine modulators in the treatment of sarcoidosis

Established and experimental medical therapy of pulmonary sarcoidosis

Neuro-ophthalmic sarcoidosis

Contact Info

Product

Resources

About